|
G |
Folh1 |
folate hydrolase 1 |
affects binding multiple interactions |
ISO |
isospaglumic acid binds to FOLH1 protein [2-(3-(1,3-dicarboxypropyl)ureido)pentanedioic acid binds to Aminocaproic Acid binds to 1-(1,3-carboxypropyl)-4,7-carboxymethyl-1,4,7-triazacyclononane binds to Valerates binds to bombesin (7-14) binds to Copper] inhibits the reaction [isospaglumic acid binds to FOLH1 protein] |
CTD |
PMID:24508213 |
|
NCBI chr 1:150,323,768...150,395,415
Ensembl chr 1:150,323,768...150,395,415
|
|
|
G |
Atg5 |
autophagy related 5 |
multiple interactions |
ISO |
N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of ATG5 mRNA] |
CTD |
PMID:31369747 |
|
NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
|
|
G |
Becn1 |
beclin 1 |
multiple interactions |
ISO |
N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of BECN1 mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of BECN1 protein] |
CTD |
PMID:31369747 |
|
NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
|
|
G |
Map1lc3b |
microtubule-associated protein 1 light chain 3 beta |
multiple interactions |
ISO |
N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in decreased expression of MAP1LC3B protein] |
CTD |
PMID:31369747 |
|
NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
|
|
G |
Sqstm1 |
sequestosome 1 |
multiple interactions |
ISO |
N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in increased expression of SQSTM1 mRNA]; N-carbamylglutamate inhibits the reaction [Carbon Disulfide results in increased expression of SQSTM1 protein] |
CTD |
PMID:31369747 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
|
G |
Ncoa2 |
nuclear receptor coactivator 2 |
multiple interactions |
ISO |
N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein]; N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr 5:5,466,544...5,696,540
Ensembl chr 5:5,616,483...5,694,598
|
|
G |
Thra |
thyroid hormone receptor alpha |
multiple interactions |
ISO |
N-benzoylalanine promotes the reaction [THRA protein binds to NCOA2 protein] |
CTD |
PMID:31566444 |
|
NCBI chr10:86,657,285...86,684,935
Ensembl chr10:86,657,285...86,684,933
|
|
G |
Thrb |
thyroid hormone receptor beta |
multiple interactions affects binding |
ISO |
N-benzoylalanine promotes the reaction [THRB protein binds to NCOA2 protein] N-benzoylalanine binds to THRB protein |
CTD |
PMID:31566444 |
|
NCBI chr15:8,890,578...9,239,815
Ensembl chr15:8,890,578...9,086,282
|
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
decreases response to substance |
ISO |
ABCC5 protein results in decreased susceptibility to Pemetrexed |
CTD |
PMID:15897250 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Alk |
ALK receptor tyrosine kinase |
affects response to substance |
ISO |
ALK gene mutant form affects the susceptibility to Pemetrexed |
CTD |
PMID:21336183 |
|
NCBI chr 6:22,696,415...23,203,791
Ensembl chr 6:22,696,397...23,203,775
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
ISO |
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with Vorinostat] results in decreased expression of BCL2 protein |
CTD |
PMID:19351772 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bid |
BH3 interacting domain death agonist |
multiple interactions |
ISO |
[Cisplatin co-treated with Pemetrexed] results in increased cleavage of BID protein |
CTD |
PMID:19351772 |
|
NCBI chr 4:153,439,812...153,465,247
Ensembl chr 4:153,442,218...153,465,203
|
|
G |
C3 |
complement C3 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 protein |
CTD |
PMID:22975265 |
|
NCBI chr 9:9,721,137...9,747,084
Ensembl chr 9:9,721,105...9,747,167
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CCL2 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO |
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of CCND1 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of CCND1 protein |
CTD |
PMID:19351772 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed] results in increased expression of CDKN1A protein |
CTD |
PMID:19351772 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
decreases response to substance |
ISO |
CFLAR results in decreased susceptibility to Pemetrexed |
CTD |
PMID:21726997 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
ISO |
DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B] |
CTD |
PMID:21726997 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Dhfr |
dihydrofolate reductase |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of DHFR mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
|
|
G |
Ercc1 |
ERCC excision repair 1, endonuclease non-catalytic subunit |
multiple interactions decreases expression |
ISO |
Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]; Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein] Pemetrexed results in decreased expression of ERCC1 mRNA; Pemetrexed results in decreased expression of ERCC1 protein |
CTD |
PMID:23912706 |
|
NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression multiple interactions |
ISO |
Pemetrexed results in increased expression of FAS protein TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]; TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein] |
CTD |
PMID:15161716 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fpgs |
folylpolyglutamate synthase |
increases response to substance |
ISO |
FPGS protein results in increased susceptibility to Pemetrexed |
CTD |
PMID:17575230 |
|
NCBI chr 3:11,717,667...11,729,694
Ensembl chr 3:11,717,667...11,723,327
|
|
G |
Ggh |
gamma-glutamyl hydrolase |
affects response to substance |
ISO |
GGH protein affects the susceptibility to Pemetrexed |
CTD |
PMID:17575230 |
|
NCBI chr 5:34,040,258...34,063,369
Ensembl chr 5:34,040,258...34,063,361
|
|
G |
Ifi30 |
IFI30, lysosomal thiol reductase |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr16:20,426,566...20,430,772
Ensembl chr16:20,426,566...20,430,752
|
|
G |
Il11 |
interleukin 11 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL11 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 1:72,636,959...72,643,255
Ensembl chr 1:72,635,267...72,643,255
|
|
G |
Il13ra2 |
interleukin 13 receptor subunit alpha 2 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL13RA2 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr X:118,443,955...118,514,716
Ensembl chr X:118,443,823...118,513,061
|
|
G |
Il1a |
interleukin 1 alpha |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1A mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
|
|
G |
Il1rl1 |
interleukin 1 receptor-like 1 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1RL1 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 9:47,133,483...47,184,316
Ensembl chr 9:47,134,034...47,182,170
|
|
G |
Il33 |
interleukin 33 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL33 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 1:248,112,611...248,147,030
Ensembl chr 1:248,132,090...248,147,029
|
|
G |
Il7r |
interleukin 7 receptor |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL7R mRNA |
CTD |
PMID:22975265 |
|
|
|
G |
Klrc1 |
killer cell lectin like receptor C1 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of KLRC1 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 4:163,453,435...163,463,718
Ensembl chr 4:163,458,528...163,463,718
|
|
G |
Kras |
KRAS proto-oncogene, GTPase |
decreases expression increases response to substance |
ISO |
Pemetrexed results in decreased expression of KRAS mRNA; Pemetrexed results in decreased expression of KRAS mRNA mutant form; Pemetrexed results in decreased expression of KRAS protein KRAS gene mutant form results in increased susceptibility to Pemetrexed |
CTD |
PMID:24688052 |
|
NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
|
|
G |
Mthfd2 |
methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase |
increases response to substance |
ISO |
MTHFD2 protein results in increased susceptibility to Pemetrexed |
CTD |
PMID:24688052 |
|
NCBI chr 4:115,004,433...115,015,965
Ensembl chr 4:115,004,448...115,015,965
|
|
G |
Npm1 |
nucleophosmin 1 |
decreases response to substance |
ISO |
NPM1 protein results in decreased susceptibility to Pemetrexed |
CTD |
PMID:24736981 |
|
NCBI chr10:18,080,949...18,091,062
Ensembl chr10:18,080,950...18,090,950
|
|
G |
Nras |
NRAS proto-oncogene, GTPase |
increases response to substance |
ISO |
NRAS gene mutant form results in increased susceptibility to Pemetrexed |
CTD |
PMID:24688052 |
|
NCBI chr 2:205,553,119...205,563,716
Ensembl chr 2:205,553,163...205,560,791
|
|
G |
Rbm17 |
RNA binding motif protein 17 |
decreases response to substance |
ISO |
RBM17 protein results in decreased susceptibility to Pemetrexed |
CTD |
PMID:16061639 |
|
NCBI chr17:70,586,345...70,603,289
Ensembl chr17:70,586,394...70,603,267
|
|
G |
Slc19a1 |
solute carrier family 19 member 1 |
multiple interactions increases response to substance |
ISO |
Pemetrexed inhibits the reaction [SLC19A1 protein results in increased transport of Methotrexate] SLC19A1 exon mutant form results in increased susceptibility to Pemetrexed |
CTD |
PMID:16505119 PMID:21879757 |
|
NCBI chr20:12,334,675...12,354,517
Ensembl chr20:12,334,676...12,352,377
|
|
G |
Slc46a1 |
solute carrier family 46 member 1 |
multiple interactions increases activity increases response to substance |
ISO |
Pemetrexed inhibits the reaction [SLC46A1 protein results in increased uptake of Methotrexate] Pemetrexed results in increased activity of SLC46A1 protein SLC46A1 protein results in increased susceptibility to Pemetrexed |
CTD |
PMID:21879757 |
|
NCBI chr10:65,728,508...65,741,708
Ensembl chr10:65,733,991...65,740,828
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFAIP3 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
|
|
G |
Tnfrsf9 |
TNF receptor superfamily member 9 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFRSF9 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 5:168,009,245...168,035,813
Ensembl chr 5:168,009,393...168,035,810
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions affects response to substance |
ISO |
TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein] TP53 protein affects the susceptibility to Pemetrexed |
CTD |
PMID:15161716 PMID:17339891 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Traf1 |
TNF receptor-associated factor 1 |
multiple interactions |
ISO |
[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TRAF1 mRNA |
CTD |
PMID:22975265 |
|
NCBI chr 3:14,003,340...14,022,955
Ensembl chr 3:14,003,340...14,022,672
|
|
G |
Tymp |
thymidine phosphorylase |
increases response to substance |
ISO |
TYMP protein results in increased susceptibility to Pemetrexed |
CTD |
PMID:17575230 |
|
NCBI chr 7:130,342,481...130,347,845
Ensembl chr 7:130,342,483...130,347,587
|
|
G |
Tyms |
thymidylate synthetase |
decreases activity multiple interactions affects response to substance |
ISO |
Pemetrexed results in decreased activity of TYMS protein TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein] TYMS affects the susceptibility to Pemetrexed; TYMS protein affects the susceptibility to Pemetrexed |
CTD |
PMID:15161716 PMID:17339891 PMID:21742432 |
|
NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
|
|